Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pressure BioSciences, Inc.    PBIO

News SummaryMost relevantAll newsSector news 

Pressure Biosciences : Pressure BioSciences, Inc. to Present at the Rodman & Renshaw 8th Annual Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
11/02/2006 | 03:15pm CEST

Pressure BioSciences, Inc. (NASDAQ: PBIO) today announced that it will present at the Rodman & Renshaw 8th Annual Healthcare Conference to be held at the New York Palace Hotel, New York, NY on November 6-8, 2006. Mr. Richard T. Schumacher, PBI President and CEO, will give a corporate overview at 9:55 am (EST) on Wednesday, November 8th. Investors will be able to hear the presentation starting on November 8th and for approximately 90 days thereafter at http://www.wsw.com/webcast/rrshq10/pbio/.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-QSB for the quarter ended June 30, 2006, in the Company's Annual Report on Form 10-KSB, as amended, for the year ended December 31, 2005, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

© Business Wire 2006
share with twitter share with LinkedIn share with facebook
share via e-mail
08/18 PRESSURE BIOSCIENCES INC : WallStreet Research(TM) Announces Availability of Upd..
08/16 PRESSURE BIOSCIENCES, INC. : Reports Second Quarter 2016 Financial Results and P..
08/15 PRESSURE BIOSCIENCES : Management's Discussion and Analysis of Financial Conditi..
08/15 PRESSURE BIOSCIENCES, INC. : to Discuss Second Quarter 2016 Financial Results an..
07/28 PRESSURE BIOSCIENCES : Announces Initial Shipments of its Enabling, Next-Generat..
06/02 STOCKNEWSNOW.COM : Publishes Business and Earnings Review Q1 2016 with Pressure ..
05/26 SEETHRUEQUITY ISSUES UPDATE ON PRESS : PBIO), Raises Price Target to $1.75
05/25 SECFILINGS.COM : Reports on Pressure BioSciences' Q1 2016 Financial Results
05/19 PRESSURE BIOSCIENCES : Reports First Quarter 2016 Financial Results and Provides..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
08/10 FTSE notches up fifth day of gains on firm financials
08/04 Business groups sue over new U.S. limit on tax-driven foreign buyouts
08/04DJBECTON DICKINSON : Tops Earnings Views, Cuts Revenue Guidance
08/04DJBECTON DICKINSON : Tops Earnings Views, Cuts Revenue Guidance
07/28DJZIMMER BIOMET : Boosts Bottom End of Earnings Forecast as Loss Narrows
More sector news : Medical Equipment, Supplies & Distribution - NEC
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 1,57 $
Spread / Average Target 293%
Consensus details
Richard T. Schumacher President, CEO, CFO, Secretary & Treasurer
Jeffrey N. Peterson Chairman
Edmund Y. Ting Senior Vice President-Engineering
Vito J. Mangiardi Independent Class II Director
Kevin A. Pollack Independent Class II Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC14.14%122 351
C R BARD INC14.91%15 990
TERUMO CORP13.48%15 924
More Results